Voyager Logo.png
Voyager Therapeutics Announces Clinical Trial Update with VY-AADC01 for Advanced Parkinson’s Disease
June 26, 2017 07:05 ET | Voyager Therapeutics
CAMBRIDGE, Mass., June 26, 2017 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ:VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe neurological...
Voyager Logo.png
Voyager Therapeutics Reports First Quarter 2017 Financial Results and Corporate Highlights
May 09, 2017 16:10 ET | Voyager Therapeutics
VY-AADC01 interim Phase 1b data recently presented at American Academy of Neurology and American Association of Neurological Surgeons meetings; program on track to report 6-month data from Cohort 3...
Taconic_Logo_Vert_Process_Medium resize.jpg
Taconic Biosciences Announces Release of New Parkinson’s Disease Animal Model
April 25, 2017 12:54 ET | Taconic Biosciences
HUDSON, N.Y., April 25, 2017 (GLOBE NEWSWIRE) -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services, announced that effective April 17, 2017, in...
Voyager Therapeutics Announces Additional Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
April 25, 2017 07:02 ET | Voyager Therapeutics
Improved Functional and Quality of Life Data Presented at the American Academy of Neurology (AAN) Meeting in Boston, MA Surgical Delivery Data Presented at the American Association of Neurological...
logo-brainhq-hi-res-hori.png
Study: More Brain Training is Better for Parkinson’s Patients
February 27, 2017 08:00 ET | Posit Science
SAN FRANCISCO, Feb. 27, 2017 (GLOBE NEWSWIRE) -- A study published online (ahead of print) in the International Journal of Neuroscience indicates that “more is better,” when it comes to brain...
Voyager Logo.png
Voyager Therapeutics Announces Updates from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
January 20, 2017 07:31 ET | Voyager Therapeutics
Cohort 3 Enrollment Complete with Increased Coverage of the Putamen Observed Cohort 3 On Track for Six-Month Data Update Mid-2017 CAMBRIDGE, Mass., Jan. 20, 2017 (GLOBE NEWSWIRE) -- Voyager...
Voyager Logo.png
Voyager Therapeutics Announces Positive Interim Results from Phase 1b Trial of VY-AADC01 for Advanced Parkinson’s Disease
December 07, 2016 16:05 ET | Voyager Therapeutics
VY-AADC01 dose-dependently improved measures of motor function and enhanced response to levodopa at six and twelve months; administration of VY-AADC01 was well-tolerated Program on track to report...
Cantabio Pharmaceuticals, Purdue Research Foundation sign cooperation agreement to investigate targeting of DJ-1 protein for treating Parkinson's disease, other neurodegenerative diseases
July 11, 2016 09:42 ET | Purdue Research Foundation
San Francisco, July 11, 2016 (GLOBE NEWSWIRE) --            SAN FRANCISCO AND WEST LAFAYETTE - Cantabio Pharmaceuticals, Inc. (OTCQB: CTBO) on Monday (July 11) announced the signing of an...
Senior Helpers Logo
New Senior Helpers In-home Senior Care to Open April 2016 In Terre Haute, Indiana
April 08, 2016 07:44 ET | Senior Helpers
TERRE HAUTE, Ind., April 8, 2016 (GLOBE NEWSWIRE) -- Baltimore-based Senior Helpers®, one of the nation's largest in-home senior care franchised businesses and a leader in personalized in-home...
NeuroDerm to Host Fourth Quarter and 2015 Fiscal Year Financial Results Conference Call on March 31, 2016
March 22, 2016 07:00 ET | NeuroDerm Ltd.
REHOVOT, Israel, March 22, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq:NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today...